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2  ABBREVIATIONS 
 
 
aHUS   Atypical hemolytic uremic syndrome 
AP   Alternative pathway of complement 
AMD   Age-related macular degeneration 
BC   Bladder cancer 
BSA   Bovine serum album 
C   Complement 
CP   Classical pathway of complement 
CR1   Complement receptor type1 
C4bp   C4 binding protein 
FH   Factor H 
FI   Factor I 
FHL-1   Factor H-like protein 1 
FHR   Factor H-related protein 
FB   Factor B 
GAG   Glycosaminoglycan  
GBM   Glomerular basement membrane  
hFH   Human factor H (β1H globulin) 
IC   Immune complex 
Ig   Immunoglobulin 
LP   Lectin pathway  
MAC   Membrane attack complex 
MBL   Mannose-binding lectin 
MASP   MBL-associated serine proteases 
MCP   Membrane cofactor protein (CD46) 
mFH   Murine factor H 
MPGN   Membranoproliferative glomerulonephritis 
SCR   Short consensus repeat unit 
SLE   Systemic lupus erythematosus  
TP   Terminal pathway 
TCC   Transitional cell carcinoma  
TTP   Thrombotic thrombocytopenic purpura
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3   ABSTRACT 
 
The major function of complement (C) is to act as a defense mechanism against 
microbes and harmful host structures. Complement gets activated through 
three pathways: classical pathway, lectin pathway, and alternative pathway 
(AP). The classical and lectin pathways are activated by surface-bound 
antibodies or lectin, respectively, while AP is spontaneously activated at a low 
rate in plasma. Due to its spontaneous initiation the AP activation must be 
strictly controlled in plasma and the regulatory protein factor H (FH) is 
responsible for this. All three pathways must also be tightly controlled on host 
cell surfaces and this is mainly accomplished by membrane-bound C regulators 
CD46, CD55, CD35 and CD59. These regulators are also utilized by tumor cells 
and in addition a number of tumor cell lines express FH. It is known that 
antigenically FH-related material is secreted by bladder cancers to urine and 
that this is used as a highly sensitive diagnostic marker for bladder cancer.  
FH is an elongated molecule consisting of 20 domains arranged like a 
string of beads. The regulatory function of FH is located in domains 1–4 and 
congenital or acquired disturbances in this region can lead to 
membranoproliferative glomerulonephritis (MPGN) type II. Recently, the 
carboxy-terminal domains 19–20 have also gained interest since it is a hot spot 
for mutations strongly associated with atypical hemolytic uremic syndrome 
(aHUS). The domains 19–20 contain one of three binding sites for C3b, one of 
three sites for heparin or glycosaminoglycans, and the main binding site for 
endothelial cells. These two kidney diseases are associated with disturbances in 
FH functions but the molecular basis for the differences has been still mainly 
unknown. 
In this thesis the role of FH as a tumor marker for bladder cancer was 
studied first. Using a panel of recombinant FH constructs we characterized the 
ligands and binding sites for the two antibodies used in the bladder cancer 
tumor marker assays BTA TRAK and BTA stat. We showed that the FH-related 
tumor marker for bladder cancer is FH itself, not any of the two other FH-
related molecules recognized by the antibodies. Furthermore, we found that 
FH-related protein-1 (FHR-1) can have an inhibitory effect in the tumor marker 
assays indicating that the clinically specific tumor marker results of the assays 
reflect a net effect of recognition of FH and inhibition by FHR-1 in the sample.  
The role of FH in protection of endothelial cells and kidney glomeruli 
was investigated to clarify why different FH mutations lead to one of the two 
kidney diseases. We first demonstrated that the binding sites for C3d and 
heparin/glycosaminoglycans on the domains 19–20 of human FH are distinct 
although partially overlapped, and that the heparin/glycosaminoglycan 
binding site mediates binding of FH to endothelial cells. These results clarify 
why mutations within that region of FH can lead to aHUS, a disease 
characterized by endothelial cell damage.  
Next we studied murine FH and found that the functions were similar 
to human FH and the sites were at the same locations as on human FH. 
Thereafter the role of FH in protection of kidney was studied by analyzing 
 12
distribution of murine FH and its recombinant constructs in vivo. We found 
that FH is specifically accumulated to kidney, also in the absence of C3 as 
shown with FH-/-C3-/- double knockout mice. We also showed that the 
acquisition of FH to the kidney is mediated by the domains 18–20, not by the 
regulatory domains 1–5. These findings suggest that the kidney glomeruli are 
specifically attacked in MPGN when no FH is present in glomeruli of when the 
FH molecules bound to glomeruli lack the regulatory activities.  
The information generated from this thesis is significant as it provides 
understanding of the physiological interactions between FH and its ligands and 
shows a role for FH as a marker for bladder cancer. More importantly, this 
thesis gives an explanation to the pathogenetic differences between two kidney 
diseases, MPGN and aHUS, both associated with defects in FH functions.  
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4  INTRODUCTION 
 
There are a great variety of microbes, viruses, bacteria, fungi and parasites, in 
our environment. The pathogenic ones can cause diseases and eventually kill 
the human host if they multiply in the body in an uncontrolled manner. 
However, the microorganisms that are encountered by a healthy individual in 
daily life are usually incapable of causing any disease. This is due to passive 
and active defense systems of the host, mainly the immune system. 
The immune system acts to protect us from infections and altered own 
cells. There are a wide variety of immune responses, which are required to 
cope with different types of pathogens. Generally, immune responses are 
divided into two categories: innate immune responses and adaptive immune 
responses. The significant differences between these are the ability of the innate 
immune responses to act in the front line of host defense by protecting the 
human body against a wide variety of microbes without previous exposure, 
and the ability of the adaptive immune responses to attack highly specifically 
one particular pathogen.  
Complement (C) is an important part of the innate immune system and 
underlies one of the major effector mechanisms of antibody-mediated 
immunity. The main physiological functions of C are to rapidly recognize and 
destroy of a wide range of invading microorganisms, and to solubilize and 
remove the immune-complexes (IC) from circulation and tissues. C gets 
activated through three pathways: classical pathway, alternative pathway (AP) 
and lectin pathway (LP). Among them, only AP is activated spontaneously in 
plasma leading to an attack against theoretically all kinds of structures exposed 
to plasma. Not surprisingly, there must be an elegant mechanism to control AP. 
If the regulation is defective, damage to host tissues and structures might 
ensue. 
Complement factor H (FH) is a key regulator of AP. The interaction 
between FH, the central C component C3b and anionic surface structures such 
as glycosaminoglycans or sialic acids is essential for AP to discriminate 
between self and non-self structures. It is also known that FH is involved in the 
immune evasion of tumor cells. 
This thesis had two aims, first, to identify the antigenically FH-related 
bladder cancer (BC) tumor marker used in two diagnostic assays (BTA TRAK 
and BTA stat), and secondly, to evaluate the impact of the interaction between 
FH, C3b and polyanions in the protection of kidney glomeruli under 
physiological conditions and in certain kidney diseases of man and mice.  
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5 REVIEW OF THE FIELD 
 
5.1 Role of the complement system in immunity 
 
The key features of acquired (or adaptive) immunity are specificity and 
immunological memory, while the innate immunity can act rapidly and 
efficiently against a wide variety of invaders. The innate immunity includes the 
complement (C) system, phagocytic cells (including macrophages, 
polymorphonuclear neutrophils, and eosinophils), natural killer cells and a 
wide array of surface receptors and soluble mediators like cytokines.  
 
Table I: Three major functions of complement system 
 
 C is considered to be a major arm of innate immunity. It is involved in 
enhancing and modulating the adaptive immune responses. It has three main 
physiological activities: defense against microbes, clearance of immune 
complex (IC) and debris, and enhancement of the adaptive immune responses 
(154), as summarized in Table I. 
 The C system was first identified in the late 19th century as the 
component of immune sera, which was heat-labile and complemented the 
effects of antibodies in bacterial lysis. Although first discovered as a part of the 
adaptive immune system, C can also become activated early in infection in the 
absence of antibodies via alternative pathway (AP) and lectin pathway (LP). 
We know now that C is a system consisting of more than 30 proteins in plasma 
and on cell surfaces. The crucial role of C in the maintenance of homeostasis is 
highlighted by the occurrence of a number of abnormalities and diseases in 
individuals with deficiencies of C proteins.  
 
5.2 Complement activation 
There are three pathways, by which C gets activated: classical pathway (CP), 
AP and LP. The three pathways differ considerably in their initial steps. 
Membrane cofactor protein (CD46)Regulation of T-mediated cell immunity and tolerance
C3 receptors on lymphocytesRegulation of T-mediated cell immunity and tolerance
C3d as a natural adjuvant for B-cell response
Modulation of adaptive immune responses
C1q; covalently bound fragments of C3 and C4Enhancement of in clearance of debris
C1q; covalently bound fragments of C3 and C4Transport of IC by CR1 on red blood cells
C1q; covalently bound fragments of C3 and C4Solubilization of IC
Clearance of immune complex (IC) and debris
Membrane-attack complex (C5b-9)Lysis of microbes or insected cells
Covalently bound fragments of C3b and C4bOpsonization and enhancement of phagocytosis
Anaphylatoxin (C3a), the receptors on leukocytesChemotaxis, enhancement of inflammatory reaction
Host defense against infection
Complement components responsible for activitiesActivities
 15
Nevertheless, all pathways lead to the formation of C3b and C5b. C5b initiates 
the terminal pathway (TP) that generates the terminal complement complex 
C5b-9 or membrane attack complex (MAC) (Fig. 1). 
Fig.1 Complement activation pathways and their regulation 
 
5.2.1 Classical pathway 
 
C1 initiates CP activation and consists of subunits C1r, C1s and C1q, the latter 
of which is capable of binding to the Fc region of certain classes of 
immunoglobulins (Ig), mainly IgG or IgM. If several arms of C1q bind 
simultaneously to Ig molecules a conformational change takes place in C1 
complex leading to activation of the enzymatic components C1r and C1s. The 
activated C1s cleaves C4 and generates two fragments, C4a and C4b (Fig. 1 and 
Fig. 2). For a short time after the generation of C4b its metastable internal 
thioester is exposed and can lead to covalent attachment of C4b to the target via 
ester or amine bond. Following binding, C4b forms a Mg2+ dependent complex 
with C2, which is cleaved by C1s to form C4bC2a, the C3 convertase of CP (111, 
182). 
IgM, IgG1, 2, 3 Mannose residues Activating surfaces
Classis Lectin Alternative
C1q, C1r, C1s
C4
C2
MBL, MASP1, MASP2
C4
C2
C3 convertase
C3(H 2O)
Factor B
Factor D
C3b
C5 convertase
C5b
C6, C7, C8, C9
Terminal
C4bC2a C3(H 2O)Bb
Properdin
C1-inh
MCP DAF CR1
C4bp FH
FI
C5b -9
Clusterin
S protein
CD59
Membrane-bound inhibitors
Soluble inhibitors
Positive regulator
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 In addition to binding to Fc part of antibodies complexed with antigen 
or forming IC, C1q can either directly bind to surface components of some 
bacteria or to C-reactive protein (CRP), an acute-phase protein of human 
plasma that binds to bacterial polysaccharides, such as pneumococcal C 
polysaccharides (156, 183, 184).  
 
5.2.2 Alternative pathway  
 
The first line of C defence against invading pathogens is AP. It is distinct from 
CP and LP in lacking a defined recognition molecule analogous to C1q or 
mannose-binding lectin (MBL). Instead, AP is continuously and non-
specifically activated at a slow rate in human plasma (84) due to spontaneous 
hydrolysis of the highly reactive thioester bond of C3 (185). In the presence of 
Mg2+ ions, the hydrolysed C3, i.e. C3(H2O) or C3b-like C3, is capable of binding 
factor B (FB) to form the initial fluid phase C3 convertase, C3(H2O)Bb (Fig. 1) (4, 
95). This enzyme cleaves C3 into C3a and C3b, the latter of which can bind 
within a short time after exposure of the metastable thioester via ester or amine 
bond to the cells nearby and interact with FB to form C3bB. Thereafter factor D 
can cleave off the Ba fragment leading to formation of the AP C3 convertase, 
C3bBb. Binding of properdin to C3bBb impedes the decay of this otherwise 
labile convertase, thereby prolongating its activity (90). The C3bBb or C3bBbP 
complexes are able to cleave more C3 to produce C3b molecules, which in the 
presence of FB form new AP C3 convertases. This leads to a positive feedback 
loop deposition of C3b on the cell surface (7, 186). To ensure that host cells are 
protected from the AP activation, this system is negatively regulated by FH, 
factor I (FI) and certain membrane-bound regulators. The mechanisms whereby 
FH regulates the AP are described in the section 3.3.3.  
 
5.2.3 Lectin pathway 
 
Activation of LP is similar to that of CP, but occurs independently of antibodies 
or C1q. MBL is a serum lectin that is somewhat similar in structure to C1q in 
consisting of several globular heads connected to each other via long and 
collagen-like stalks. MBL-associated serine proteases (MASP), MASP-1, MASP-
2 and MASP-3 are found in complex with MBL. MBL is capable of binding 
strongly to microbial surfaces that contain a high number of repetitive terminal 
mannose, fucose and/or N-acetylglucosamine residues. Those structures are 
typical for certain organisms such as Saccharomyces cerevisiae, Candida albicans, 
E.coli K12, and Salmonella typhimurium (157). MBL does not bind to mammalian 
cell surfaces due to the non-repetitive arrangement of the carbohydrates and 
the presence of terminal sialic acid residues. Binding of MBL-MASP complex to 
a ligand activates MASP2, that cleaves C4 to C4a and C4b and C2 to C2a and 
C2b and whereby the CP C3 convertase C4b2a is formed (Fig. 1) (61, 187-189).  
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Formation of C5 convertases initiates TP and all three activation pathways are 
converged at this stage (Fig. 1). The C5 convertase of CP is C4b2a3b, a tri-
molecular complex (25), while that of the AP is C3bBb3b complex (19, 53). 
Cleavage of C5 releases the small peptide fragment C5a, which is a potent 
anaphylatoxin (190) while C5b propagates the cascade. The final step of the C 
activation is the formation of MAC (99). From the C5b step onwards the 
formation of MAC is non-enzymatic. C5b binds C6, forming C5b6, and the 
complex then binds C7 to form the C5b-7 complex, which becomes 
hydrophobic and preferentially inserts into a membrane (106, 123). Thereafter, 
C8 binds to this complex, followed by a stepwise addition of up to 12 C9 
molecules, these form a functional pore C5b6789n abbreviated to C5b-9n (18, 
134). The complex can also form in the fluid phase but polymerization of C9 
does not occur in the absence of a membrane. 
 
5.2.5 C3 and C3b fragments produced by FI  
 
C3 is pivotal to all the three activation pathways (Fig. 1). It is present in serum 
at a concentration of approximately 1.2 mg/ml, the highest concentration of 
any C component. C3 is a glycoprotein that consists of one α- and one β-chain 
of 115 kDa and 75 kDa, respectively. The chains are linked together by 
disulphide bridges. C3, C4 and C5 belong to the same superfamily, of these, C3 
and C4 contain a metastable internal thioester, which is critical to the function 
of these proteins (Fig. 2) (102, 103).  
 
Fig. 2 C3b/C4b and their fragments cleaved by factor I   
Factor I
R
O thioester bond
C3b
FH
CR1
MCP
iC3b
2 kDa C3f
64 kDa 40 kDa
fluid phase bound 
CR1
C3dg
27 kDa 40 kDa
C3c
40 kDa
α
β
α 
β 
γ
C4bp
CR1
MCP
fluid phase bound 
C4b
C4d
α
β 
γ
C4c
R
O
R
O R
O
R
O
R
O
 
5.2.4 Terminal pathway  
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 C3 is cleaved into a 181 kDa C3b by C3 convertase of either CP or AP 
by removal of a 9 kDa C3a, an important anaphylatoxin, from the amino 
terminus of the α-chain. This induces a rapid conformational change thereby 
exposing the thioester bond of C3b accessible to any nucleophilic molecules, 
such as H2O, or hydroxyl group or amino group (16). This allows covalent 
binding of C3b to a wide range of biological surfaces. If C3b fails to attach to a 
surface the thioester undergoes hydrolysis leading to the generation of fluid-
phase C3b incapable of covalent surface attachment (110). The deposition of 
large amounts of C3b on the target surface plays a central role in the biological 
functions of C (Table I). 
 Factor I (FI), also called C3b inactivator, cleaves C3b at a total of four 
distinct sites (72). For all the cleavages, FI needs a cofactor, either FH, C3 
receptor type1 (CR1), or membrane cofactor protein (MCP, CD46). All these 
three cofactors catalyze the first two cleavages of C3b, generating iC3b and C3f, 
while only CR1 is responsible for the last two cleavages resulting in the release 
of C3c from the bound C3dg (15, 72). Therefore, CR1 is needed for the FI-
mediated cleavage of iC3b (Fig. 2). Under physiological conditions the surface-
bound 41kDa C3dg is not converted into C3d and C3g by FI indicating that 
C3dg, not C3d, is the usual final breakdown product found in serum. However, 
C3dg can be cleaved into C3d and C3g by other serine proteases, such as 
trypsin, plasmin or elastase (15, 17, 191).  
 
5.3 Complement regulation 
 
The enzymatic stages of the C cascade and especially the AP amplification loop 
are very efficient in producing a large number of C activation products and 
deposits on the target surfaces. Therefore it is critical that this system is tightly 
regulated and directed only against foreign structures and damaged or altered 
host material and not against viable host cells or other structures. C activation 
is partially controlled by the inherent instability of the convertases, which only 
possess proteolytic activity for a relatively short time, and by the metastable 
nature of the thioester sites of C4b and C3b allowing attachment to the target 
surface only for the some milliseconds (93, 94). A group of C control proteins in 
plasma and on host cell surfaces are, however, essentially needed to control C 
at various stages to prevent over-consumption and damage to the bystander 
structures. In fact nearly half of C proteins are involved in the regulation of C 
activation (Fig. 1).  
  
5.3.1 Complement regulation in fluid phase 
 
The activation of CP is mainly regulated by serine protease inhibitor, C1 
inhibitor, which irreversibly binds to C1r and C1s causing their dissociation 
from the C1 complex and subsequently down regulation of CP (12). CP and LP 
are also regulated by the C4b binding protein (C4bp), which is a large plasma 
glycoprotein. First, C4bp acts as a cofactor for FI in the proteolytic inactivation 
of C4b thereby preventing the formation and reassembly of the classical C3 
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convertase (C4b2a) (Fig. 1) (115). Second, C4bp accelerates the decay of C4bC2a 
convertase on cell surfaces and prevents the formation of new convertases (5). 
In addition, C4bp can also, to some extent, act as a cofactor for FI in the 
cleavage of C3b in fluid phase thereby inhibit to some extent AP (69, 116, 243). 
However, C4bp is not able to replace FH, which is the major inhibitor of AP in 
the fluid phase. 
 The activation of AP is mainly regulated in the fluid phase by FH and 
to some extent by factor H-like protein 1 (FHL-1). FH is responsible for the 
control of both fluid phase and surface-associated activation of AP. Since FH 
plays an essential role in the regulation of AP and is involved in all the 
publications in this thesis, a more detailed description of FH is given in the 
section 3.3.3.  
 Two proteins can inhibit the formation of terminal complement 
complex or MAC in the fluid phase. S protein, also known as vitronectin, binds 
to nascent C5b-7 in fluid phase before it attaches to a membrane. It forms SC5b-
7 complex, which is unable to insert to lipid bilayers (101). Clusterin, also called 
as SP-40, has multiple functions including the clearance of cell debris and lipid 
transport (245). As a regulator of C activation, similar to S protein, clusterin 
binds to C5b-7 and prevent its insertion to cell surface (246). 
 
5.3.2 Surface-associated regulation 
 
The C activation on own cell surfaces is tightly down-regulated by the 
combined action of membrane-bound and soluble regulators. Membrane 
bound regulators include DAF (CD55), MCP (CD46), CR1 (CD35) and protectin 
(CD59) (Fig. 1). 
 
5.3.2.1 Membrane cofactor protein (CD46) 
 
MCP is a transmembrane glycoprotein and that down-regulates C activation on 
host tissues. It performs this function by acting as a cofactor for FI-mediated 
cleavage of C3b and C4b. The wide tissue distribution of MCP reflects the 
critical function of host cell protection. With the exception of erythrocytes, all 
the cell types and tissues examined so far have expressed this protein. A recent 
discovery of CD46 deficiency predisposing to atypical hemolytic uremic 
syndrome (aHUS) highlights the importance of CD46 in C regulation.  
 
5.3.2.2 Decay accelerating factor (CD55) 
 
DAF is a glycosyl-phosphatidyl-inositol-anchored membrane inhibitor of C 
composed of four domains called short consensus repeat domains (SCR). DAF 
down-regulates C activation by interfering with the function of C3- and C5-
convertases of both the classical and alternative pathways (159). It is widely 
expressed on tissues as well as on T and B lymphocytes, macrophages, 
dendritic cells and red blood cells (108, 159). DAF has a broad clinical 
relevance. For example, a defect in the synthesis of glycosyl-phosphatidyl-
 20
inositol anchor in a bone marrow cell lineage leads to lack of surface-bound 
DAF and CD59 on blood cells resulting in paroxysmal nocturnal 
hemoglobinuria (PNH). Recently, it has been described that DAF plays a role in 
modulating T-cell immunity (247).  
 
5.3.2.3 Protectin (CD59) 
 
CD59 regulates C cascade at the final step, inhibiting formation of MAC on cell 
surfaces. This protein, being anchored to the cell membrane via a glycosyl-
phosphatidyl-inositol anchor (13), is expressed ubiquitously on circulating, 
endothelial, epithelial and stromal cells (32, 81, 89).  
5.3.2.4 Complement receptor type 1 (CD35) 
 Human CR1 (also called C3b receptor, CD35) is a large, multifunctional 
glycoprotein, which is composed mainly of 30 extracellular SCR domains (77). 
CR1 is the most versatile inhibitor of both classical and AP C3 and C5 
convertases due to its decay-accelerating activity and cofactor activity for both 
C3b and C4b cleavages (96). Moreover, CR1 plays a major role in IC clearance 
due to its high affinity for C3b and C4b and filamentous structure stretching 
outwards from the erythrocyte membrane (2, 112). 
 
5.3.3 FH in the regulation of AP 
 
FH is an essential down-regulator of AP in plasma and seems also to play an 
important role in the protection of host cells and tissues from C attack.  
 
5.3.3.1 Structural analysis of FH 
 
FH was first identified by Nilsson and Muller-Eberhard as β1H globulin (128). 
It consists of a single polypeptide chain (155 kDa) and is present in plasma at a 
high concentration (110-615 mg/ml). Analysis of translated cDNAs of human 
and murine FH shows that the proteins consist of 1213 and 1216 amino acids, 
respectively, and share 63% sequence identity at the amino acid level (23, 79). 
Both the proteins possess a number of potential glycosylation sites. Human and 
murine FH molecules are composed of 20 SCRs organized like beads on a 
string (Fig. 3). Each SCR domain consists of approximately 60 amino acids and 
is connected to the neighbouring domain with a linker of three to eight amino 
acids. The X-ray crystal and nucleomagnetic resonance structures of several 
SCRs have shown that the domains are globular structures with five 
antiparallel â-strands connected with loops and turns (20, 42, 75). 
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Fig. 3 Schematic structure of FH and FHL-1 and its functional sites 
 
5.3.3.2 Expression of FH 
 
FH is primarily produced by liver (23, 79). Extrahepatic synthesis of FH has 
been demonstrated in number of tissue and several cell lines such as 
endothelial cells (36, 85), fibroblasts (21), monocytes (26), kidney cells (34), glial 
cells (91). Approximately 10% of FH synthesis is extrahepatic. It is thought that 
the local synthesis of FH helps to protect the tissues from C attack. 
 It has been shown that some carcinomas and a number of tumor cell 
lines express or acquire elsewhere expressed FH (51, 139, 160, 161). 
Interestingly, detection of antigenically FH-related molecules in urine has been 
exploited in diagnosis of individuals with transitional cell carcinoma (TCC) of 
the urinary bladder (51, also see study I of this thesis). 
 
5.3.3.3 Function of FH 
  
The most prominent function of FH is the inhibition of AP activation. FH 
inhibits C activation through three mechanisms that serve either to prevent 
formation of the AP C3 convertase or to accelerate its dissociation (10, 11, 87). 
In the early stage, FH can compete with factor B for binding to C3b, therefore 
preventing formation of the C3 convertase C3bBb. FH can also bind to the 
formed convertase and accelerate dissociation of the complex (decay-
accelerating activity). The most important role for FH in down-regulation of AP 
seems, however, to be the role in acting as a cofactor for FI in irreversible 
inactivation of C3b.  
 FH regulates C activation both in the fluid-phase of plasma and on 
cellular surfaces. In plasma, the formed C3 (H2O) and C3b molecules are 
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efficiently inactivated by FH acting as a cofactor for FI mediated cleavage. If the 
C3b binds to a surface its inactivation by FH and FI is dependent on the 
properties of the surface. If binding of FH is promoted by the surface C3b is 
inactivated whereas if binding of FH is not promoted factor B binds to the C3b 
molecule leading to propagation of the activation.  
 
5.3.3.4 Main interactions of FH  
 
FH is involved in numerous interactions via its multiple binding sites. These 
interactions include (a) controlling C activation by binding to C3b (141) and 
additionally on host surfaces by binding to polyanions or at the sites of tissue 
damage to C-reactive protein (132, 133), (b) acting as a ligand for L-selectin 
(193), (c) acting as an adhering molecule for human neutrophils by binding to 
an integrin receptor CD11b/CD18 (54, 194). Factor H is also exploited by a 
number of pathogenic organisms that protects themselves from C mediated 
destruction by binding FH with their proteins or carbohydrates. Certain SCRs 
within FH are responsible for these interactions or functional properties, many 
of which have already been localized and are summarized in Fig. 3. 
 As described above, some C3b is deposited spontaneously and 
indiscriminately onto theoretically all kinds of structures, which get into 
contact with plasma. However, it has been demonstrated decades ago that AP 
is capable of discrimination between self and non-self structures mainly based 
on the interaction between FH, C3b and the surface where C3b is bound. The 
non-activator self structure has been demonstrated to be rich in sialic acids 
and/ or glycosaminoglycans (GAGs) such as heparin sulphate. These anionic 
structures are thought to increase the affinity of FH binding to C3b deposited 
on the particles or cell surfaces, thereby negatively regulating the C activation 
on the surfaces (8, 9, 33, 135, 163).  
 There are totally three binding sites on FH for heparin at SCR7, SCR20 
and within SCR8-15, presumably at SCR9 (27, 44, 55). The important role of 
heparin binding for the physiological function of FH is obvious since it is 
possible to convert an activator surface into a nonactivator surface through 
associating heparin onto it (6). However, the role of each of the heparin binding 
site in physiological function of FH has not previously been shown.  
 For a long time it was considered that sialic acids and heparin share a 
common binding site on FH, and heparin was used as a model for the sialic 
acid binding. However, it was recently shown that the recombinant construct 
of FH containing SCRs 1-15, and thereby at least two heparin binding sites, did 
not bind to sialic acids on Neisseria gonorrhoeae at all (64). Therefore, the sialic 
acid binding site was located within SCRs 16-20 by exclusion. It still remains 
unknown weather the sialic acid and heparin binding sites on the C-terminus 
of FH are identical and if they mediate different biological functions or not. 
However, it is evident that sialic acids are specifically involved in the 
recognition of self structures by AP (9, 83, 163).  
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5.3.3.5 FH protein family 
 
Human FH is encoded by a 4.4 kb mRNA transcript (23). Northern-blot 
analysis of human liver RNA using FH specific probes has lead to the 
identification of seven additional transcripts of 5.5, 5.0, 3.0, 2.2, 2.0, 1.8 and 1.4 
kb (29, 142). The cDNA of the 1.8 kb species consists of 1644 base pairs and 
encodes a 43 kDa protein, named FH-like protein 1 (FHL-1) (58). Sequence 
analysis of FHL-1 revealed that it is identical to the first seven SCRs of FH, with 
the exception of four additional amino acids (Ser-Phe-Thr-Leu) at the carboxy-
terminus. The production of FHL-1 is a result of alternative splicing of the FH 
gene (Fig. 3) (24, 30, 38). The proteins derived from the other identified cDNA 
stretches are structurally and antigenically related to FH and was named FH-
related (FHR) proteins 1-4 (Fig. 4) (28, 30, 31, 38, 39, 41, 65). 
 Recently, an analysis of pathological human glomerular preparations 
has revealed the presence of an additional FHR, FHR-5. This 62 kDa protein 
corresponds to the 3 kb liver transcript and contains 551 amino acids, which are 
organized into 9 SCRs that are homologous to FH and other FHRs (Fig. 4) (142). 
 
Fig. 4 Factor H protein family 
 
5.4 Complement and disease 
 
There are many kinds of human diseases where C activation has been shown to 
occur at certain stages of the pathological processes. The activation and 
regulation of C are finely balanced in order to allow activation on the surface of 
an invading organism while limiting the activation on the host cells and 
tissues. When the mechanisms that regulate this elegant balance are impaired 
the C system may cause cell or tissue injury and predispose to disease.  
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5.4.1 Complement and infection 
 
Deficiencies of C components can cause increased susceptibility to infections 
via three mechanisms. First, if the deficiency leads to impaired generation of 
surface-bound C3b molecules it is associated with defective opsonic activity of 
C resulting in an increased general susceptibility to infection caused by 
pyogenic microorganisms (105, 113). Secondly, if the deficiency compromises 
the lytic activity of C it increases susceptibility to neisserial infections (109, 121, 
126).  
 C regulators play an important role in protecting host cells from the 
deleterious effects of C activation. On the other hand, many microorganisms 
may take advantage of C regulators to enhance their virulence. Some viruses 
and intracellular bacteria utilize the C regulators as means to enter the cells 
(192). Pathogenic microorganisms may also utilize essential host regulators to 
control C activation on their own surfaces. For example, the binding of FH and 
FHL-1 to microbial surface allows the organism to directly and rapidly 
inactivate newly formed C3b molecules on the surface. A number of 
microorganisms, such as Streptococcus pyogenes (22) (63), S. pneumoniae, S. 
agalactiae, Neisseria gonorrhoeae (52) (64), Yersinia enterocolitica (74), Borrelia 
burgdorferi sensu lato, Echinococcus granulosus (43) and human 
immunodeficiency virus (HIV) can acquire FH and/or FHL-1 and therefore 
evade the AP activation of the host (47, 48, 70). 
 
5.4.2 Complement and inflammatory diseases  
 
Tissue injury as a result of, for example, trauma or infection can induce C 
activation. This can enhance the damage by leading to release of three 
anaphylatoxins, C3a, C4a and C5a, or deposition opsonic C3b-molecules or 
pore-forming MAC complexes. The anaphylatoxins stimulate mast cells and 
basophils to produce vasoamines leading to local vasodilatation and increased 
capillary permeability. These changes in addition to the chemotactic effects of 
C3a and C5a promote migration of the inflammatory cells to the site of injury. 
These effects are seen in many diseases and here two situations are discussed 
as examples. 
 
5.4.2.1 Complement and ischemic injury  
 
Ischemia, or actually the post-ischemic reperfusion, leads to C activation. 
Tissue necrosis that follows ischemia leads to an altered lipid bilayer in the 
damaged tissue that can directly act as a C activator and, on the other hand, 
lead to a decreased number of the membrane-bound C regulators. 
 There are several studies on experimental models demonstrating that 
the inhibition of C activation reduces the extent of tissues destruction upon 
reperfusion after ischemia (124, 166). The same is seen in some therapeutic 
studies with C inhibitors (244). However, the usefulness of C inhibition in 
ischemia-reperfusion injury in humans in vivo remains to be verified (59, 167). 
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5.4.2.2 Complement and systemic lupus erythematosus 
 
It has been widely accepted that the activation of C by IC is an important 
mechanism leading to tissue damage in patients with systemic lupus 
erythematosus (SLE) (117). C1q and other C components, such as C4, are 
needed for efficient removal of apoptotic cells. Deficiencies of these 
components are strongly associated with reduced clearance of apoptotic cells 
and an SLE-like syndrome (104, 118, 168). Although the mechanisms 
underlying the recognition and elimination of apoptotic cells by C1q and CP 
have been intensively studied, more work is needed to understand the 
pathogenesis of SLE (169).  
 
5.4.3 C and age-related macular degeneration  
 
Recently a significant association between FH polymorphism and age-related 
macular degeneration (AMD) has been reported (218-220). AMD is the most 
frequent cause of irreversible blindness in the elderly. Although the 
pathogenesis underlying the AMD is unknown, it has been shown that the 
main factor for it is a variant FH, FHH402Y (cDNA mutation T1277C). The amino 
acid 402 of FH is located at SCR7, a domain shared by FH and FHL-1. That 
domain contains or contributes to three interactions of FH, for heparin, M-
proteins, and CRP (Fig. 3). The concentration of FHL-1 in plasma is 10-50 
µg/ml (35) and although FHL-1 has not been shown to have any major 
physiological role it would be interesting to analyze whether  the mutation in 
FHL-1 plays a role in the development of AMD. It would also be interesting to 
know which of the binding characteristics of SCR7 are altered in the H402Y 
variant. 
 
5.4.4 Complement and cancer  
  
The human C system is capable of recognizing and attacking tumor cells 
through C-dependent cytotoxicity or C-dependent cellular cytotoxicity. The 
attack may be initiated through CP by binding of C1q to IgG or IgM bound to 
the tumor cell surfaces. The C activation may be further amplified by AP. This 
can eventually lead to killing of the tumor cells through the formation of MAC 
pores (158, 221). Moreover, these processes can enhance the cellular immune 
responses by the chemotactic and cell-activating anaphylatoxins, such as C5a 
(222). 
 To overcome this powerful immune surveillance, tumor cells have 
evolved sophisticated C evasion mechanisms. It has recently been shown that C 
regulators contribute to protection of tumor cells by several ways. The majority 
of solid tumor cells are found to express membrane-bound C regulators CD46, 
CD55 and CD59(60, 92, 223-225). In addition, a number of tumor cell lines have 
been shown to produce FH and FHL-1, for example, glioblastomas, 
myosarcomas, neuroblastomas, ovarian tumor cells, cervix carcinomas, bladder 
TCC, and lung cancer cells (46, 51, 91, 107, 160, 226, 237). Some of the reports 
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have described a significant role for the expression of C regulators in C 
resistance of the tumor cells. It has also been shown that antigenically FH-
related material is secreted by bladder TCC into urine and that this is a highly 
sensitive marker for bladder cancer (51, 217). Two diagnostic kits, BTA stat and 
BTA TRAK, utilize this phenomenon by detecting the FH-related material by 
two monoclonal anti-FH antibodies. However, the exact target antigen has 
remained unknown. 
 
 
5.4.5 C and kidney diseases  
 
It has been appreciated for several decades that C is involved in the 
pathogenesis of several kidney diseases, especially of glomerular diseases. Role 
of C in human kidney pathology has become evident by three types of clinical 
observations. First, Ig and C component depositions are often co-localized in 
human renal biopsies providing circumstantial evidence that C plays a key role 
in kidney diseases (234). Second, in certain kidney diseases total serum C 
activity or levels of individual C components are typically affected (82). Third, 
deficiency of certain C components is often associated with kidney diseases 
(154, 155). Furthermore, contemporary molecular biological tools such as 
production and use of genetically manipulated mice and recombinant proteins 
have clearly indicated that C is involved in several glomerular diseases (149). 
Finally, rational inhibition of C is being applied clinically to human kidney 
diseases (see section 5.4.6). 
 A number of different clinical presentations are associated with 
defective AP control. Usually the leading disorder in those cases is a renal 
disease. The most common renal disease with AP activation is IgA 
nephropathy but in the pathogenesis of that disease AP activation occurs 
probably secondary to the IgA depositions. The best characterized other kidney 
diseases with AP activation are atypical hemolytic uremic syndrome (aHUS) 
and membranoproliferative glomerulonephritis types I and II (MPGN I; MPGN 
II). In these diseases genetic mutations or functional defects of the various 
regulators of C3b or C3-convertase such as the fluid phase regulators FH and 
FHL-1, the membrane regulator MCP, and the serine protease FI, have been 
reported. In addition, autoantibodies that stabilize the active C3 convertases 
C3bBb can cause MPGN II.  
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Fig.5 Schematic structure of kidney glomeruli and hypothesis for MPGN II 
 
5.4.5.1 Structure of kidney 
 
The kidney is a highly vascular organ with a specialized capillary bed that 
filters plasma to generate excreted urine containing unnecessary and harmful 
substances. The kidney can be divided functionally into (a) glomeruli, the 
actual filter units of the kidney, (b) the tubules, which transport the urine and 
perform reabsorption of useful substances such as water, and (c) the 
interstitium, the space between the tubules and glomeruli containing mainly 
blood vessels, immune cells and fibroblasts. Glomeruli are critical in 
maintaining the homeostasis of body. They are composed of capillary 
endothelial cells, glomerular basement membrane (GBM), podocytes, and 
mesangial cells (Fig. 5). The first step of filtration takes place through the 
endothelial cell layer of the capillary wall. There are numerous small openings, 
fenestrations, between the endothelial cells leading to direct exposure of GBM 
to plasma. Next the primary filtrate traverses the secondary filter, GBM. The 
last filter is composed of the visceral epithelial cells called podocytes. 
Podocytes have a highly specialized structure with major processes and foot 
processes which organized into so-called slit diaphragm.  
 Collagen type IV acts as a structural framework of normal GBM and as 
a size-selective filtration to plasma proteins that are larger than 150 kDa. It 
provides mechanical stability for the GBM and a framework for proteoglycans 
and glycoproteins (122, 238, 239). The core proteins and GAGs concentrate in a 
regular lattice-like network and give the GBM a negative overall charge that 
prevents, for example, aggregation of blood cells in the glomeruli. The most 
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abundant GAG in GBM is heparan sulphate (Fig. 5), which is responsible for 
approximately 90% of the negative charge. Heparan sulphate has also been 
suggested to acquire plasma FH to GBM to provide C regulation on and within 
GBM but this has not been directly shown. While cellular structures in 
glomeruli and other parts of kidney are protected by membrane-bound C 
regulators, GBM is lacking these regulators and therefore it has been postulated 
that FH participates in the protection of kidney glomeruli from C activation via 
protecting GBM.  
 
5.4.5.2 Membranoproliferative glomerulonephritis type II 
 
MPGN can be divided into three subtypes on the basis of electron microscopic 
appearance of GBM. Type I is characterized by subendothelial dense deposits, 
type II has intramembranous dense deposits, and type III has both 
subendothelial and subepithelial dense deposits. Individuals with FH 
deficiency may present either with MPGN I or MPGN II indicating that these 
two types might reflect different stages of the same disease. Here the focus will 
be on MPGN II. 
 MPGN II, also called dense-deposit disease (DDD), is a relatively rare 
kidney disease. It is characterized by the depositions of C containing electron-
dense material within GBM followed by capillary wall thickening, mesangial 
cell proliferation and glomerular fibrosis (195). Clinically the disease usually 
presents with persistent proteinuria and hematuria, common to a nephritic 
syndrome. These symptoms are not specific for MPGN, and histopathological 
examination of a kidney biopsy is mandatory for the diagnosis.  
 An association between defective control of AP and MPGN II has been 
observed a long time ago (56, 100, 120). The mechanism underlying defective 
control of AP relevant to MPGN II could be (a) C3 nephritic factor (C3NeF), a 
group of IgG autoantibodies, which bind and stabilize the C3 convertase of AP 
(73, 76) (b)genetic deficiency of FH (c) or an autoantibody that blocks the C3b 
binding site on FH (82). 
 To date, FH deficiency has been reported from 29 MPGN cases in 12 
families. The disorder is usually associated with a reduced plasma 
concentration of FH (5-10% of normal) and only occasionally a total FH 
deficiency has been observed. Due to the absence of FH C3 is continuously 
activated at a high rate resulting in consumption of C3 and reduced level of FB 
and components C5-C9. Consequently, the total or subtotal FH deficiency 
could manifest similarly to C3 deficiency with recurrent bacterial infections (1, 
67, 130). Some cases of SLE have also been reported in patients with combined 
FH and C2 deficiencies (71, 165). However, the leading disorder caused by FH 
deficiency is MPGN II. (146, 164). So far, genetic mutations of the FH-coding 
HF1 gene have been reported from a total of seven MPGN II patients from five 
families (80, 164). In addition FH deficient pigs (150) and knockout mice (138) 
suffer from kidney diseases similar to MPGN II.  
 The molecular basis for the absence or reduced level of FH protein in 
plasma of the patients with MPGN II has recently been intensively analyzed. 
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The mutation of a conserved cysteine residue needed for the integrity of the 
SCR domain has led to failure of secretion of the resulting protein and its 
retaining in the endoplasmic reticulum (66, 164, 196). These results indicate that 
the disulfide bond formation is critical for the transportation and secretion of 
FH in plasma. In addition, mutations in other than cysteine residues can lead to 
the failure in protein secretion as identified in FH deficient pigs (147). 
 An AP dysfunction-associated factor was purified from plasma and 
urine of a patient with hypocomplementemic MPGN II (82). The circulating 
factor was further identified as a monoclonal Ig λ light chain dimer (λL), which 
directly bound to FH but not to the C3 convertase of AP. The binding site was 
localized on SCR3, the regulatory region of FH, leading to inactivation of the 
regulatory function of FH (136). 
 In most cases of MPGN II, the defective regulation of AP is associated 
with C3NeF (197, 198). C3NeF is an IgG autoantibody that stabilizes the AP C3 
convertase by increasing its half-life approximately10-fold (88). It is now well 
recognized that healthy individuals can have low amounts of autoantibodies 
associated with different autoimmune disorders (199, 200). This is the case with 
C3NeF as well, since this kind of autoantibodies can occasionally be found in 
healthy newborns and adults (201, 202).  
 
5.4.5.3 Atypical hemolytic uremic syndrome  
 
Thrombotic microangiopathies are disorders characterized by arteriolar and 
capillary wall thickening, swelling or detachment of the endothelial cells from 
the basement membranes, deposition of fluffy material in the subendothelial 
space, and intraluminal platelet thrombosis that partially or completely 
obstructs the vessel lumina. Depending on whether renal or brain lesions 
prevail, two pathologically nearly indistinguishable but clinically different 
manifestations are known: hemolytic uremic syndrome (HUS) and thrombotic 
thrombocytopenic purpura (TTP) (203, 204). The common characteristics for 
HUS and TTP are microangiopathic hemolytic anemia, thrombocytopenia, and 
thrombotic obstruction of microvasculature of various organs. The clinical 
manifestations dominated by renal failure are usually referred as HUS while 
those showing predominantly neurological involvement are referred as TTP 
(205, 206).  
 Most cases of HUS represent the typical form of HUS that is caused by 
Gram-negative bacteria, which produce shiga or shiga-like toxin (Shigella 
dysenteriae and Escherichia coli O157). This form is generally self-limiting with a 
good outcome. The other form of HUS is atypical since it is not associated with 
bacterial toxins. It is often recurring, sometimes familial, and has usually a poor 
outcome (153). This form is referred to as atypical HUS (aHUS), familial HUS, 
or recurrent HUS.  
 Patients with either typical or atypical HUS have usually reduced 
plasma C3 levels and C3 fragment depositions in the microvasculature of 
glomeruli (207, 208). However, in typical form of HUS, C3 level returns to 
normal when the patient is in remission, while in the atypical form the C3 level 
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remains consistently low, even between the clinical relapses (114). This 
indicates that AP is overactivated in aHUS. Recently, genetic analyses have 
revealed that aHUS is associated with mutations of several genes encoding for 
proteins that control the activity of the alternative pathway convertase C3bBb; 
i.e. FH (114, 148, 209, 210), MCP (211, 212), and FI (213). Among these 
mutations the heterozygous mutations in the carboxy-terminus of FH are most 
often found in aHUS, in approximately 15-20% of patients diagnosed with 
aHUS. In addition, autoantibodies binding to FH have been reported in some 
aHUS patients (214). It has been shown that FH mutations associated with 
aHUS cluster in the C-terminal part of FH, mainly SCR20 (209, 216). This 
domain is important for the binding of FH to endothelial cells (152). 
  
5.4.5.4 Complement activation in kidneys in animal models 
  
Experimental animal models have been and are widely used in studies on 
kidney diseases. Earlier, animal studies were limited to naturally occurring 
deficiencies of individual proteins, such as Norwegian Yorkshire pigs deficient 
in FH (150). Recently, the studies with genetically manipulated mice have 
highlighted the important role that C regulators play in glomerular C 
protection in vivo (50, 138).  
 Norwegian FH deficient pigs provided the evidence of a causal 
relationship between the defective control of AP and the development of fatal 
glomerulonephritis within the first few weeks of life (150, 241). Biochemical 
analyses showed the absence of FH in plasma and genetic analyses identified 
homozygous mutations within SCR9 and SCR20 of FH (147). The mutated 
proteins were synthesized but secretion was blocked intracellularly resulted in 
the absence of FH from plasma.  
 More recently FH deficient mice were generated by targeted 
interruption of the murine FH gene (138). As expected, the mice presented with 
uncontrolled C3 activation, and even the heterozygous FH +/- mice showed 
some features of AP activation. As early as four days after the birth deposition 
of C3 and C9 was detectable in the glomeruli of the FH-/- mice, but at that stage 
the renal histology was normal. By the age of eight months the mortality was 
significantly higher in the FH-/- mice compared to the control littermates and all 
the FH-/- mice developed MPGN characterized by subendothelial dense 
deposits. To verify that the uncontrolled C3 activation caused by FH deficiency 
is essential for the development of MPGN in mice, double knockout mice 
deficient in both FH and FB were generated. As hypothesized, in the double 
knockout mice C3 activation was prevented and the mice were completely 
protected from the development of MPGN. 
 On the basis of the animal models it is evident that FH is needed for 
the protection of kidney glomeruli from the AP attack. The molecular 
mechanisms how FH mediates the protection remain still controversial. On the 
basis of the published animal models it is possible that the role of FH in 
preventing the glomerular pathology is only in preventing vigorous activation 
of AP in plasma but it is also possible that the role of FH is more specific within 
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the glomeruli and especially GBM. These issues are hard to be explored in 
humans and therefore to answer those questions an additional animal model 
would be needed.  
  
5.4.6 Therapeutic manipulation of the complement system  
 
Inappropriate activation of C occurs in a large number of inflammatory, 
ischemic and other diseases. In many of these pathological processes, C has a 
major contribution to the initiation, amplification or perpetuation of tissue 
damage. It is evident that an effective and safe therapeutic agent for preventing 
or reducing C activation is needed. The most promising or most studied 
strategies for therapeutic C inhibition are (i) C depletion by overconsumption, 
for example by cobra venom factor, CVF (127, 141, 170) (ii) administration of a 
recombinant or purified human C regulator, (iii) administration of humanized 
monoclonal antibodies that inhibit C activation or its specific secondary effector 
functions, and (iv) synthetic peptides inhibiting C activation. Here the focus 
will be on the second strategy. 
 
5.4.6.1 Heparin and therapeutic implication in kidney disease 
 
Heparin is a polyanionic carbohydrate widely used as an anticoagulant. It has 
long been known to inhibit C in vitro (227). Heparin inhibits C activation at 
multiple stages, by binding and inactivating C1, blocking assembly of C3 
convertases and inhibiting formation of MAC (228-231). Only a few studies 
have addressed the potential use of heparin as an anti-C agent in vivo. Weiler 
and colleagues showed that heparin is much more efficient inhibitor of human 
than guinea pig C in vitro but they did not explore the therapeutic potential of 
the finding (37). 
 One of the most remarkable features of MPGN II is the expansion of 
extracellular matrix and the proliferation of mesangial cells. It has been shown 
that in vivo administered heparin and related GAGs suppress the formation of 
extracellular matrix and the proliferation of mesangial cells. In addition, these 
molecules can reestablish the negative charge of GBM and podocytes and 
prevent C activation in experimental and clinical renal diseases (178-181). 
Apparently, it is very attractive to test weather heparin or related GAGs could 
be utilized as therapeutic agents to prevent or inhibit the development of 
MPGN II. 
 
5.4.6.2 Other C inhibitors  
 
The enzymatic components of the C1 complex, C1r and C1s, are attractive 
targets for specific protease inhibitors and, in fact, C1 inhibitor was the first 
clinically used C inhibitor for the reconstitution therapy in hereditary 
angioedema (HAE) (129, 131). A number of groups have screened synthetic 
and natural libraries for small molecular weight inhibitors of C1r and/or C1s 
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and a synthetic C1s inhibitor has been shown to block CP in vitro and also to 
inhibit the pathology of HAE in vivo (171, 172). 
 The membrane-bound C regulators have also been explored as 
potential therapeutic agents. The soluble extracellular parts of these proteins, 
when expressed as recombinant constructs, usually retain full function but fail 
to target to certain cell surfaces. The best characterized, and the only one that 
has been tested in human pathology is soluble CR1 (119, 124). Although the 
agent proved to be safe, the its effects on the disease were somewhat 
disappointing (173, 174). Recombinant, soluble forms of MCP and DAF have 
also been generated and shown to be effective in inhibiting C in vitro and in 
various animal models of C-mediated diseases (40, 175, 176). Although a 
soluble form of CD59 (sCD59) has also been produced (177), it is a poor 
inhibitor of C in plasma This is because CD59 prevents MAC formation or cell .  
 FH is a potent inhibitor of AP in plasma and the level of functional FH 
is decreased in certain kidney diseases, such as MPGN II and aHUS. However, 
the concentration of FH in plasma needs to be high (> 100 µg/ml) to efficiently 
prevent systemic AP activation. Therefore it is not surprising that FH has not 
been evaluated as a therapeutic systemic inhibitor of C but, similar to soluble 
CR1, it might be useful in local inhibition of C activation, for example in 
various forms of arthritis. This potential of FH remains, however, to be studied. 
In addition, since a FH-/- knockout mouse model for MPGN II is available, it 
would be very interesting to aim at generating more potent recombinant 
derivatives of FH and to test the therapeutic potential of these constructs in 
preventing or attenuating the disease pathology. 
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6 AIMS OF THE STUDY 
 
The main aim of this study was to analyze the role of FH in certain human 
kidney and urinary tract diseases. 
 
 
The specific aims were: 
 
(i) To identify the antigenically FH-related bladder cancer tumor 
marker in the diagnostic BTA stat and BTA TRAK assays, 
(ii) To functionally characterize murine FH and compare it with 
human FH in vitro and thereby provide a basis for the setup of 
a murine animal model for aHUS,  
(iii) To analyze the detailed mechanism how FH binds to 
endothelial cells and thereby to clarify the role of the 
interaction in the molecular pathogenesis of aHUS, 
(iv) To study the role of FH in the protection of glomeruli in vivo by 
studying distribution of murine FH and its recombinant 
fragments in wildtype and FH-knockout mice.  
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7 MATERIALS AND METHODS  
 
7.1 Materials 
 
7.1.1 Chemicals 
 
All chemicals used in the thesis were of analytical or molecular biology reagent 
grade. Bovine serum album, trypsin, and soybean trypsin inhibitor were from 
Sigma Chemical Co., St. Louis, MO, USA. Penicillin, streptomycin, and L-
glutamine were from BioWhittaker, Verviers, Belgium. Endoglycosidase H was 
from Roche Applied Science (Mannheim, Germany). Heparin, dextran sulphate 
(m.w. 8,000 Da), chondroitin sulphate A, chondroitin sulphate B, chondroitin 
sulphate C, fucoidan, keratan sulphate, colominic acid, dextran, and heparin-
albumin (3-6 mol heparin per mol albumin) were from Sigma. 
  
7.1.2 Buffers and media 
 
Buffers and media were prepared into double-distilled water and sterilized by 
either autoclaving for 15 min at 1210C or, for heat labile ingredients, filtering 
through 0.22 μm filters (Millipore, Bedford, MA, USA). Phosphate buffered 
saline (PBS), pH 7.4, contained 140 mM NaCl, 5 mM Na2HPO4 and 5 mM 
KH2PO4. Veronal buffered saline (VBS), pH 7.4, contained 5 mM veronal and 
145 mM NaCl. Buffered methanol medium with yeast extract (BMMY) 
contained 10 g of yeast extract (Oxoid) and 20 g of peptone were combined in 
700 ml of water and autoclaved. Once cooled, 100 ml of 1 M potassium 
phosphate buffer, 100 ml of filter sterilized yeast nitrogen base (134 g/L), 100 ml 
of filter sterilized 5% methanol and 2 ml of filter sterilized biotin (200 μg/ml) 
were added to the solution. Yeast-peptone-dextrose agar (YPD agar) contained 
10 g of agar, 10 g of yeast extract, and 20 g of peptone combined with 900 ml of 
water. After autoclaving the solution was cooled and 100 ml of filter sterilized 
1.1 M dextrose was added and the solution was poured onto plates. Before use, 
zeocin was added onto the plates to achieve a final concentration of 100-200 
μg/ml. Yeast extract peptone dextrose medium (YPD) was prepared similarly 
but without adding agar.  
 
7.1.3 Human samples 
 
Standard midstream voided urine samples were obtained from four patients 
with histopathologically confirmed transitional cell carcinoma (TCC) of 
bladder (Institutional Ethical Review Board acceptance #300896). After 
collection, the urine samples were immediately frozen to –70oC and stored 
frozen until the experiments were performed. The normal human urine, 
normal human serum, and FHR-1 deficient serum were obtained from 
consented Caucasian labworkers. 
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7.1.4 Proteins 
 
Human FH (hFH) (used in articles I, II, III) was either purified using the 
previously described methods (78) or purchased from Calbiochem Corp. (La 
Jolla, CA,). Human FI (used in article II) was purchased from Calbiochem. 
Human C3 (hC3) (used in articles II and III) purchased from Calbiochem Corp. 
(La Jolla, CA). Murine and human C3 (mC3 and hC3) were isolated from fresh 
frozen mouse and human plasma essentially as described for hC3 (78). Murine 
FH was purified from fresh-frozen mouse plasma by rat anti-mouse FH mAb-
coupled CNBr-activated Sepharose 4B beads (Pharmacia), as described in 
articles II and IV. Protein concentrations were measured using the BCATM 
protein assay kit (Pierce, Rockford, IL, USA) and ELISA-reader (Spectramax, 
Molecular Devices, Munich, Germany). If needed, the proteins were dialyzed 
with a microdialyzer from BRL technologies Inc (Gaithersburg, MD, USA). 
 
7.1.5 Antibodies 
 
The primary antibodies used in the studies are summarized in Table II. The 
following secondary antibodies were used: peroxidase-conjugated rabbit anti-
mouse IgG, donkey anti-goat IgG, and mouse anti-rat IgG were purchased 
from Jackson ImmunoResearch Laboratories, West Grove, PA, USA. FITC-
labeled mouse anti-rat IgG was also from Jackson ImmunoResearch 
Laboratories. FITC-labeled goat anti-mouse F(ab´)2 fragment and rabbit anti-
goat IgG were from DAKO A/S, Glostrup, Denmark. 
 
Table II: Primary antibodies used in the study 
 
 
7.2 Production of recombinant proteins 
 
III
I
I
IIBethyl lab. TX 
I Calbiochem. La jolla 
III
III
IIArticle II 
IIArticle II 
I
I
Used in 
mouse, mAb, to SCR18 of hFHVIG8
mouse mAb to SCR1 of hFH90X
mouse mAb to SCR8-11 of hFH131X 
goat, pAb against to mC3 anti-mC3 
goat pAb against hFH anti-hFH 
mouse, mAb, to SCR18 of hFH 3D11
mouse mAb to SCR20(?) of hFHIXF9 
rat mAb, to SCR1-5 of mFH 5C2 
rat mAb, to SCR18-20 of mFH 10E9 
mouse mAb, to SCR3 of hFH, and 
SCR3 of hfHL-1 
X13.1
mouse mAb, to SCR18 of hFH and 
SCR3 of hfHR-1 
X52.1
Reference Description Antibody
(51)
(51)
(139  )
(13 9 )
(62)
(62)
(62)
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The used recombinant human and murine FH constructs and hFH mutants are 
summarized in Table III. Some of the recombinant proteins were produced by 
collaborators either in Spodoptera frugiperda Sf9 insect cells using the 
baculovirus expression system or in Pichia pastoris yeast cells (Invitrogen) (145). 
Mutations in FH15-20 were introduced using QuikChange Site-directed 
mutagenesis Kit (Stratagene, Amsterdam, The Netherlands) (162, 232). 
 Four overlapping cDNA fragments of mFH were amplified by PCR 
performed in a Gene Amp ® PCR System 9700 (Perkin Elmer Applied 
Biosystems, Foster City, CA, USA) using a mouse liver cDNA library as a 
template (Stratagene, La Jolla, CA). The amplified cDNA was cloned into 
pCR2.1 cloning vector (Invitrogen). The sequence of the cloned cDNA was 
verified from three separately prepared clones using automatic sequencing. 
The full-length mFH cDNA was assembled from four parts by ligation of 
restriction enzyme cleaved overlapping cDNA fragments. 
 The full-length cDNA of mFH was used as a template for PCR-
amplification of the DNA coding for the amino-terminal SCRs 1-5 of mFH 
(mFH1-5) or the carboxy-terminal mFH18-20. The purified PCR products were 
cloned into the expression vector pPICZaB (Invitrogen, Carlsbad, CA) to 
generate the specific constructs. After sequencing, the plasmids were 
transformed into Pichia pastoris strain X33 according to the manufacturer’s 
instructions. The recombinant proteins were expressed in BMMY medium with 
daily addition of 1% methanol (v/v) before harvesting at approximately 72 
hours. The supernatants containing the expressed proteins were collected and 
subjected to purification. 
 
Table III: Recombinant proteins used in the study 
III
III
II
I
I
I
I
Reference
IIIbaculovirusSCRs15-20hFH15-20
IIbaculovirusSCRs1-5 hFH1-5
II and IVPichia pastorisSCRs1-5 mFH1-5
IIIPichia pastorisMutations at K1230S and R1231A FH15-20 mut B
IIIPichia pastorisMutations at R1203E, R1206E, and 
R1210S 
FH15-20 mut A
IIIbaculovirusMutations at R1203E, R1206E, 
R1210S, K1230S, R1231A 
FH15-20 mut AB
II and IVPichia pastorisSCRs18-20 mFH18-20
IPichia pastorisSCRs19-20 hFH19-20
I and IIPichia pastorisSCRs18-20 hFH18-20
I and IIbaculovirus SCRs8-20 hFH8-20
Ibaculovirus SCRs1-6 hFH1-6
Ibaculovirus SCRs1-4 hFH1-4
Ibaculovirus SCRs1-4, no SCR2 hFH1-4Δ2
Ibaculovirus SCRs1-4, no SCR3 hFH1-4Δ3
Ibaculovirus SCRs3-5 hFH3-5
IbaculovirushFH-related protein-1 hFHR-1
Used in articleExpression systemDescriptionName of protein
(62)
(62)
(145) 
(145)
(62)
(145)
(62)
(162)
(162)
 37
7.3 Purification of recombinant proteins 
 
Murine and human FH18-20 constructs were purified by heparin affinity 
chromatography using HiTrap Heparin columns (Amersham Pharmacia 
Biotech, Uppsala, Sweden) as described earlier (62). Subsequently, mFH18–20 
and hFH18–20 were deglycosylated by incubating 100 µg of the constructs in 
100 µl in the presence of 0.5 mM endoglycosidase H (Roche Applied Science, 
Mannheim, Germany) (see article II). The constructs mFH1-5 and hFH1-5 were 
purified by ProbondTM nickel chelate purification system according to the 
manufacturer’s standard protocol (Invitrogen). 
 
7.4 Production of monoclonal antibodies 
 
Two 6-week-old rats of AO/OlaHsd strain (Harlan, Zeist, The Netherlands) 
were immunized with a mixture of 280 µg of purified mFH1-5 and mFH 18-20 
in the presence of complete Freund's adjuvants. After 4 weeks the rats were 
given boosters of approximately 200 µg of each of the constructs mixed with 
incomplete Freund’s adjuvant. Four days after the third booster one rat was 
splenectomized and 1 x 106 splenocytes were fused with 1.5 x 106 rat myeloma 
cells (YB.2 cell line) using the standard protocol (97). The anti-mFH IgG 
producing rat hybridoma cell lines were identified and subjected to two rounds 
of subclonings to obtain pure cell clones. The 10E9 clone produced IgG against 
mFH18-20 and the 5C2 clone produced IgG against mFH1-5. The antibodies 
were purified from hybridoma supernatants by protein G affinity 
chromatography (Amersham Pharmacia Biotech). 
 
7.5 Labeling of proteins 
 
The proteins hC3, mFH, mFH1-5 and mFH18-20 (articles II and IV) were 
radiolabeled with Na125I (NEN, Boston, MA, USA) according to the standard 
Iodogen method (233). Free 125I was separated from the labeled protein by 
running through Sephadex G25 column (Amersham Pharmacia Biotech) once 
for the in vitro studies or twice for the in vivo studies. 
 
7.6 Immunofluorescence microscopy 
  
For immunofluorescence microscopy, 5 µm cryosections were prepared using 
Cryomicrotome (Meyer Instruments, Inc. Houston, TX, USA) and SuperFrost 
object slides (Menzel-Glaser GmbH, Braunschweig, Germany). The sections 
were fixed by incubating them for 5-10 min in -200C acetone bath. After air-
drying a primary antibody (10E9 or 5C2), diluted to 20 µg/ml with PBS, was 
added and the slides incubated for 30min at 27oC in a humidified chamber 
followed by three washes with PBS. Next, fluorescein isothiocyanate (FITC) -
labeled mouse-anti-rat IgG (Jackson), diluted 1:200 in PBS containing 1% BSA, 
was added and incubated at 22oC for another 30min followed by the same 
washing procedure as for the primary antibody. After mounting with 90% 
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glycerol in PBS the sections were examined using an Olympus BX10 fluorescent 
microscope (Olympus Optical, Tokyo, Japan) as described earlier (82) (see also 
article IV). 
 
7.7 Cell culture and flow cytometry 
 
Human umbilical vein endothelial cells (HUVECs) were obtained from 
American Type Culture Collection (ATCC) and cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, BioWhittaker, Verviers, Belgium) 
supplemented with 10 % FCS, 300 U/ml penicillin, 300 µg/ml streptomycin, 
and 6 mM L-glutamine (all from BioWhittaker) at 37°C in the presence of 5% 
CO2. The adherent cells were harvested by incubation for 10 min at 37°C with 
PBS containing 0.2 mg/ml EDTA. The cells were washed twice with PBS and 
resuspended in FACS blocking buffer (½ PBS with 1% BSA).  
 For each flow cytometric analysis 1x106 HUVECs in 100 µl of the FACS 
blocking buffer were first incubated for 30 min with either the ligands alone 
(article II) or with the ligands together with an inhibitor (article III). After 
washing with 900 µl of the buffer the cells were centrifuged and resuspended 
to a solution containing 20µg/ml primary antibody. After 30 min incubation at 
220C the cells were washed and the FITC-labeled secondary antibodies were 
added. After 30 min incubation on ice the cells were washed, resuspended in 
300 µl of the buffer. The data were obtained by FACScan (Becton Dickinson, 
Heidelberg, Germany) and analyzed using CellQuest software (Becton 
Dickinson).  
 
7.8 Surface plasmon resonance analyses 
 
Surface plasmon resonance analyses were performed using Biacore® 2000 or 
Biacore® 3000 instruments (Biacore AB, Uppsala, Sweden) and the data was 
analyzed using BiaEvaluation 3.0 software (Biacore AB). Carboxymethylated 
dextran chips were used in all the assays (Sensor Chips CM5, research grade, 
Phamacia Biosensor AB, Uppsala, Sweden).  
 The coupling procedure was performed using flow rate of 5 µl/min. 
The coupling started with an activation step where 35-70 µl of fresh solution 
containing N-hydroxylsuccinimide and N-ethyl-N’-dimethyl-aminopropyl-
carbodiimide (NHS-EDA, Phamacia Biosensor AB) was injected. Thereafter the 
proteins to be coupled were injected at concentrations of 10-100 µg/ml (diluted 
or dialyzed in 10-20 mM acetate buffer, pH 4.2). Usually 10-50 µl of the solution 
was needed for the wanted coupling efficiency. Afterwards, the chip was 
deactivated by injecting 35-70 µl of 1 M ethanolamine-HCl (pH 8.5). The 
continuous running buffer (1/3 PBS or ½ PBS) was degassed before use. 
 The proteins for the binding assays were dialyzed against the used 
running buffer and centrifuged (5 min at 14,000 g) to remove possible 
aggregates. About 10 μl of each protein was injected separately into a control 
flowcell, which had been activated and deactivated but without any protein 
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coupled (so called blank channel), and into the flowcells coupled with the 
proteins at 22oC or 37oC.  
 
7.9 Cofactor activity assay 
 
Cofactor activity of murine FH and its fragments for human FI in the cleavage 
of radiolabeled hC3b was examined by using a standard procedure (14). 
Briefly, mFH (0.3 ⎧M) or mFH1-5 (0.3 ⎧M or 3 ⎧M) together with FI (20 ⎧g/ml) 
was incubated with 125I-labeled-hC3 (10 ng, 105 cpm), as described in detail in 
article II. 
 
7.10 Mouse strains 
 
The wild type C57BL/6 mice (WT) were purchased from Harlan (Zeist, The 
Netherlands). The FH knockout mice (FH-/-), and the FH/C3 double knockout 
mice (FH-/-C3-/-) were generated on129/Sv × C57BL/6 genetic background at 
the Imperial College School of Medicine, London, UK (138). In Helsinki the 
knockout mice were bred and maintained at the animal facilities of Haartman 
Institute or of the Faculty of Veterinary Medicine, University of Helsinki. The 
general principles of laboratory animal care were carefully followed in the 
experiments and the FH-/- mice were subjected to repeated urinalysis to detect 
possible proteinuria. The experiments were carried out according to the 
guidelines and with the permissions from the ethical committee of animal 
experiments, University of Helsinki (permissions #138/02 and #180/03).  
 
7.11 Procedures for the animal experiments 
 
The age of the mice used for the in vivo studies was 3-9 months. Two kinds of 
experiments were performed. First, distribution of radiolabeled mFH or mFH 
constructs was analyzed at the whole body level using in vivo scintigraphy of 
mice or on the organ level using counting of radioactivity in the organs after 
sacrifying the animals. Second, in vivo distribution of radiolabeled mFH or 
mFH constructs was analyzed on histological level using in situ 
autoradiography of selected cryosectioned organs. 
 
7.11.1 In vivo injections 
 
Three different 125I-labeled proteins, mFH purified from mouse serum, 
recombinant mFH18-20, or recombinant mFH1-5, were injected into either the 
WT mice, the FH-/- mice, or the FH-/- C3-/- mice. Approximately 24 hours before 
the injections, the mice were given drinking water containing 100 µg/ml of 
potassium iodide to block collection of possible released or free 125I to the 
thyroid gland. The drinking water iodide was not given to the mice meant for 
the in vivo scintigraphy since detection of the location of thyroid gland could be 
useful for interpreting the results. The 125I-labeled proteins were injected into 
the tail vein in a total of 100µl of PBS (for the in vivo scintigraphy) or 
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intraperitoneally in a total of 250 µl (for the organ distribution or in situ 
autoradiography).  
 
7.11.2 In vivo scintigraphy 
 
After intravenous administration of 6-20 µCi of 125I-labeled protein (specific 
activity of 0.5-5 x 107 cpm/µg) the mice were anesthetized and imaged at 
various time points. The images were detected from the ventral (anterior-
posterior) view from each mouse at 1, 4, and 24 hours and counts were 
collected for 30 minutes per image. Imaging was performed with a low energy 
high resolution collimator on 30keV γ-energy peaks (35% window) with Picker 
Prism 1500 XP γ-camera (Picker International, Highland Heights, OH, USA) 
utilizing Odyssey software. Matrix size of 512x512x16 was used for imaging, 
making the pixel size on the images 0.44 x 0.44 mm.  
 
7.11.3 Monitoring the in vivo organ distribution 
 
For monitoring the organ distribution of radiolabeled mFH or its recombinant 
constructs either the animals used for the in vivo scintigraphy were sacrificed 
or, to obtain a larger number of animals in each group, a separate set of animals 
were sacrificed after injected intraperitoneally the same labeled proteins. After 
sacrifying, the organs were collected, weights of the organs were measured and 
the level of radioactivity in each organ was measured using a γ-counter. The 
accumulated radioactivity was calculated per mg of tissue (cpm/mg).  
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8 RESULTS 
 
8.1 Factor H is a urinary tumor marker for bladder cancer  
 
Bladder cancer is one of the most common cancers and the five-year survival 
rate is relatively low. Apparently, a sensitive method for early detection of 
bladder TCC, particularly the carcinoma in situ tumors is needed. BTA TRAK™ 
and BTA Stat® (Alidex, Redmond, WA, USA) are two commercially available 
assays for detection of one or more bladder tumor antigens in urine. These 
antigens were known to be antigenically related to FH but the identity of the 
particular tumor marker or markers was not known. For example, the marker 
could have been any of the seven FH family proteins. The aim of the first study 
was to identify the exact FH-related tumor marker of TCC. 
 BTA TRAK and BTA Stat are enzyme immunoassays, in which mAb 
X52.1 is used as the capturing antibody while mAb X13.2 is used as the 
detecting antibody. Using a panel of recombinant FH constructs it was 
demonstrated that mAb X52.1 binds to SCR18 of FH and to FHR-1 while X13.2 
binds to SCR3 of both FH and FHL-1 (article I). Since FHR-1 was recognized by 
the capture antibody X52.1 we studied if FHR-1 inhibits the FH-dependent 
signal in the BTA TRAK assay. We observed that the presence of FHR-1 
inhibited somewhat the test signal. Since the capturing mAb X52.1 binds to the 
C-terminal part of FH that also contains a binding site for C3b and C3d we next 
studied if these C3 fragments could inhibit binding of X52.1 to FH. No 
competition was found and therefore it was concluded that C3-fragments in 
urine or blood should not interfere the diagnostic assays.  
 Finally, when FH was specifically taken out from a positive sample 
using immunoaffinity chromatography the sampled turned negative although 
all the FHRs and FHL-1 were left intact in the sample. This proved that the 
tumor marker for TCC is FH, and nothing but FH. 
 
8.2 Functional characterization of mouse FH 
 
Although FH deficiency or mutations in the FH coding gene can lead to 
development of two kidney diseases, MPGN or aHUS, it is still poorly known 
what is the role and molecular mechanism of FH in protection of kidneys, 
especially the glomerular structures. Therefore, a mouse model would be a 
useful approach for studying the role of FH in vivo. Murine factor H (mFH) was 
first cloned by Kristensen and Tack in 1986 (79). However, functional 
properties of mFH have not been studied only superficially. In order to study 
the role of FH in the protection of kidney glomeruli and thereby to aid in 
further analysis of the pathogenesis of FH-associated diseases in vivo we aimed 
at studying the key functions of mFH and comparing those with the functions 
of hFH. 
 Using recombinant mFH and hFH constructs representing the N-
terminus we showed that cofactor activity of both of these molecules for C3b 
interaction is mediated by the N-terminal five SCRs (article II). We also showed 
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that the C-terminal heparin/glycosaminoglycan binding property and C3b-
binding property were shared, and that SCRs 18-20 of both murine and human 
FH bind to human umbilical vein endothelial cells. Therefore the results show 
that the key functions of murine and human FH molecules in AP regulation are 
similar and located in analogous. 
 
8.3 FH binds to endothelial cells via the C-T heparin binding site 
 
It is apparent that the C-terminal region of FH is critical for the fully 
functioning intact protein since FH mutations associated with aHUS cluster in 
SCRs 19-20 (148, 151, 216). It has been shown that the C-terminal region of FH 
is critical for the target or host recognition by AP (144) and for the surface 
attachment of FH to endothelial cells (152). In addition it is striking that the two 
most C-terminal domains are conserved and highly homologous in all the five 
FHR proteins (137). However, it is not known which is the functional loss 
leading to the development of aHUS when there is a mutation at the C-
terminus of FH. Therefore our aim was to study the relations between the 
binding sites for heparin, C3b/C3d, and endothelial cells at the C-terminal 
region of FH. 
 Using a sample from an aHUS patient, who is heterozygous for FH 
mutant lacking SCR20 (FH-E1172Stop), we found that FH-E1172Stop mutant 
bound heparin with a clearly weaker affinity than wildtype FH, indicating that 
SCR20 is essential for intact binding of full length FH to heparin (article III). We 
had earlier shown that the heparin and C3b/C3d binding sites are closely 
located in SCR20 and probably partially overlapping (162). Using surface 
plasmon resonance assay we found that several polyanions could inhibit the 
binding of FH15-20 not only to heparin but also to C3d. These results indirectly 
show that specificity of the heparin/glycosaminoglycan binding site on SCR20 
is not restricted to heparin and that the site is partially overlapping with the 
C3d binding site. However, C3d could not inhibit the binding of FH15-20 to 
heparin and we found a monoclonal antibody 3D11 that binds to SCR18-20 and 
inhibits binding of FH to heparin but not to C3d. These results indicate that the 
binding sites for heparin and C3d are distinct although evidently partially 
overlapping. 
 Since the heparin and C3d binding sites were partially distinct we 
analyzed whether either of the sites mediates binding of FH to endothelial cells 
using flow cytometric analyses. While heparin and Fab fragment of the 3D11 
mAb inhibited binding of FH to HUVEC cells, C3d did not reduce binding of 
FH to the endothelial cells at all. This indicates that the heparin binding site on 
SCR20 of FH, and not the C3d binding site, mediates the interaction of FH with 
the endothelial cells. 
 
8.4 In vivo studies of FH distribution in mouse model  
 
Recently, genetic and functional studies on aHUS and AMD patients have 
shown that FH has an important role in protection of certain host structures, 
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and that a clinical disease can occur under circumstances where this protection 
fails locally or systemically. The article III clearly showed that FH plays a role 
in protecting endothelial cells from AP attack by binding to the cells via the C-
terminal heparin binding site. On the other hand we showed in the article I that 
FH is found in normal human urine and especially in TCC patient urine. 
Therefore FH is evidently at least transiently found in glomerular structures. It 
remained still open, however, if FH had a specific role in protecting glomeruli 
from AP attack. To answer this question we used the obtained data from the 
article II and the elsewhere described FH-knockout (FH-/-) and FH/C3 double 
knockout (FH-/- C3-/-) animals to set up study IV.  
 First we raised novel monoclonal rat anti-mFH antibodies and used 
them in immunofluorescence microscopy of WT, FH-/- and FH-/- C3-/- mice. We 
observed FH in kidney glomeruli of the wildtype mice while in the kidneys of 
the knockout mice no signal was visible. FH was located in glomeruli of the 
WT mice at or near GBM or the glomerular endothelial cells. Next we 
investigated if the localization of mFH to kidney glomeruli is specific compared 
to other organs and, using the FH-/- C3-/- mice, if it is dependent of C3. To study 
this, 125I- labeled mFH or recombinant mFH1-5 or mFH18-20 were injected 
intravenously or intraperitoneally to three types of mice (WT, FH-/- and FH-/- 
C3-/- mice) and the distribution was followed using scintigraphy, counting the 
radioactivity in different organs. 
 We observed that the 125I-labeled mFH protein and mFH18-20 construct 
were acquired to kidney glomeruli while the 125I-labeled mFH1-5 construct 
failed to become enriched in the glomeruli. The phenomenon was probably 
quick but easy to detect only when nonspecific activity in blood circulation had 
disappeared within the first 24 hours after the injection. The results indicated 
that mFH was specifically accumulated to kidney in vivo, even in the absence of 
C3 or C3-derived depositions, and that this accumulation was mediated by the 
C-terminal part of mFH. 
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9 DISCUSSION 
 
9.1 FH in immune evasion mechanisms and therapy of BC 
 
Complement can play an important role in immune surveillance against 
tumors but tumor cells, however, use several strategies to circumvent 
complement attack (235). One of the best-understood of these strategies is the 
expression of membrane-bound C regulators DAF, MCP and CD59 (45, 57, 60, 
236). Recently, also intrinsic or plasma-acquired FH and FHL-1 have been 
implicated in protection of tumor cells against immune lysis (46, 51, 91, 107, 
160, 226, 237). One type of tumor cell lines that have been reported to produce 
FH are TCC-derived cell lines (51, 143, 217). Role of FH as a protector of these 
cells from C attack in vivo has not been shown but the phenomenon is made 
significant by the finding that FH secreted to urine by TCC can act as a urinary 
tumor marker for this malignant disease (article I).  
The clinically used FH-tumor marker immunoassays, BTA TRAK and 
BTA Stat, utilize two anti-FH mAbs, X52.1 and X13.2, as the capturing and 
detecting antibody, respectively. We showed that X13.2 bound to SCR3 of FH 
and FHL-1 while X52.1 bound to SCR18 of FH and to FHR-1 (article I). 
However, it remains to be studied if the over-production of FH by the TCC 
cells is important for the survival or pathogenesis of TCC tumors. It also 
remains open if FH-neutralizing agents, e.g. monoclonal anti-FH antibodies, 
could be used as therapeutic agents in bladder cancer. 
FH has three distinct inhibitory roles in the C cascade. First, it makes 
C3b cleavable by FI by acting as a cofactor, both in solution and on certain 
surfaces. Second, FH accelerates the decay, i.e. breakdown of the active C3 
convertase, C3bBb, leading to irreversible detachment of Bb from the complex. 
Third, FH competes with FB in binding to C3b. It has previously been shown 
that the two anti-FH mAbs utilized in the TCC tumor marker tests, X13.2 and 
X52.1, exert interesting effects on the biochemistry of C activation in an in vitro 
system (143). X13.2 inhibits strongly FI-mediated cleavage of C3b, in which FH 
acts as an essential cofactor. This function of FH has been localized to SCRs 1–4 
(49, 145). Therefore, our result showing that X13.2 binds to SCR3 of FH gives an 
explanation for this interference. However, previously it was thought that it is 
a paradox that the X13.2 mAb strongly inhibits C-mediated lysis as well (143). 
This effect could be, however, easily explained by overconsumption of C in the 
serum following elimination of FH by the mAb. A nearly identical situation has 
been seen previously with the patient-derived anti-FH mini-autoantibody, 
protein LOI (82, 140). By binding to SCR3 of FH, the protein LOI inhibited FH 
cofactor function and led to uncontrolled C activation. Within the first few 
minutes of incubation the hemolytic activity of C was increased, followed by a 
rapid decrease and extinction of the hemolytic activity over the subsequent 10–
20 minutes. It is highly likely that the X13.2 mAb exerts its effects by the same 
mechanism. By contrast, the previous work demonstrated that the X52.1 mAb 
actually enhanced the strength of association between FH and surface-bound 
C3b (143). This could be due to dimerization of FH by the antibody and the 
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thereby increased avidity of the FH-Ab-FH complex to the C3b molecules on a 
surface. Unlike X13.2, X52.1 had no effect on cleavage of fluid-phase C3b. This 
is in agreement with our results showing that X52.1 does not compete with C3d 
or C3b in binding to FH. Despite this, X52.1 is capable of enhancing C-
mediated lysis of various cell types by up to 10-fold (143). This led to the 
hypothesis that the inhibitory activity of X52.1 was specific for the decay-
accelerating (cell-surface) activity of FH. However, it is possible that the effect 
is caused by interference of the FH-surface association by the X52.1 mAb since 
its binding site on SCR18 is adjacent to the cell and heparin binding site on 
SCR20 of FH. Therefore it seems that X52.1 inhibits binding of FH to certain 
cells, but not to C3b/C3d, indicating that the C-terminal C3b/C3d binding site 
and the cell recognition sites are distinct. This is concordant with our 
observations about the hierarchy of the C-terminal binding sites in article III. 
It is encouraging that mAb X52.1 is able to enhance the C-mediated 
killing of several TCC-derived cell lines in vitro (143). Of course this mAb 
cannot be used systemically in the treatment of TCC since it would lead to 
disturbances in normal FH functions in plasma and possibly even to kidney 
pathology. This does not exclude a possible role for the mAb in local therapy of 
TCC, for example by injecting the mAb to the bladder postoperatively. 
Nevertheless, the other C inhibitors than FH, mainly the membrane-bound 
regulators DAF, MCP and CD59, seem to be more attractive in utilization of 
complement-mediated cytotoxicity in cancer therapy (139, 158, 226). 
 
9.2 FH deficiency in MPGN II 
 
So far genetic mutations of FH gene in patients with MPGN II have been 
reported in a total of eight patients from five families and, in addition, in two 
animal models, i.e. FH deficient pigs and FH knockout mice (table IV). In 1997, 
Ault et al provided the first description of a molecular mechanism for FH 
deficiency in MPGN II. In that patient mutations in the framework cysteine 
residues caused the block in FH secretion (66). Notably, FH-related MPGN II 
was found to associate only with homozygous deficiency, while aHUS was 
found to associate with both heterozygous and homozygous deficiency. The 
mechanism underlying this difference remains unknown. Studies on the piglets 
and mice deficient of FH showed that all the animals developed MPGN II 
spontaneously (138, 150). Introduction of a targeted interruption in the gene 
encoding complement FB in the FH knockout mice prevented the AP activation 
and development of MPGN. The central role of tight C3bBb regulation in the 
prevention of MPGN II is also supported by the studies on a 57-yr-old woman 
with MPGN II. In that study, a mini-autoantibody in the form of a monoclonal 
Ig ⎣-light chain dimer was identified. The protein bound to SCR3 of FH causing 
a vigorous AP activation and C3 overconsumption (98, 140). Taken together, it 
is most likely that massive C3 activation in vivo is essential for the development 
of FH-associated MPGN II. However, the reason why just glomerular basement 
membrane becomes attacked has remained unrevealed. 
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It has been shown that the glomeruli are the only site of C3 deposition 
in FH deficient mice, suggesting that the GBM and/or glomerular endothelial 
cells have a unique requirement for protective role of FH (138). Our study on 
wildtype and FH deficient mice in vivo in the article IV demonstrated for the 
first time that plasma FH is specifically acquired by kidney, most likely by 
glomeruli. Binding of FH to glomeruli is mediated by the carboxy-terminal 
SCRs 18-20. This finding explain why the AP activation is focused on glomeruli 
when FH is lacking or when the circulating and GBM-binding FH molecules 
lack the regulatory activities due to a mutation or an autoantibody. GBM is a 
complex lattice mainly composed of collagen type IV, laminin and heparan 
sulphate (240). It is clear that all the components of AP and TP have access to 
GBM in sufficient amounts to support the formation of massive complement 
deposition in the absent of FH activity (241). Fluid phase heparan sulphate has 
been shown to facilitate binding of FH to target surfaces (33). On the basis of 
the article IV we know that FH is specifically acquired to glomeruli by its 
carboxy-terminal end, most probably the heparin-binding site on SCR20.  
Obviously there is some C3b deposited to GBM by spontaneous AP activation 
under physiological conditions and this indicates that the protection of GBM 
against AP may be critically dependent on the ability of FH to recognize the 
GBM-bound C3b molecules. In the absence of FH, multiple C3b molecules 
become firmly bound to GBM and serve as subunits for C3 convertases, leading 
to amplification loop of AP. The complement deposition process is most 
probably responsible for the formation of electron-dense deposits within GBM  
(168)MPGN IIundetectablemouse2002 
(150)MPGN IIundetectablepig1995
(164)MPGN [2]undetectable222004
( 68) (66)MPGN I0111995
(65)
(1)
(71)
(125)
(80)
(3)
Reference 
Cutaneous SLE, N. meningitidis
meningitis [1]
N. meningitidis meningitis[1]
SLE nephritis [1]a, normal [1]a
microscopic hematuria [1]
MPGN [3], 
N. meningitidis sepsis [2]
Atypical MPGN II [2]
Vasculitis,thrombocytopenia [1], IgA 
nephropathy [2]
Clinical phenotypeFactor H levelNumber of 
families 
Number of 
patients
Year 
reported
undetectable111996
<1%
<1%
undetectable
<10%
37-73%
1
3
3
2
3
11989
11988
11987
11986
21982
a Coexisting heterozygous C2 deficiency
Table IV: FH-deficiency MPGN and other diseases (excluding aHUS)
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in the kidneys of patients with MPGN II. The electron dense material might be 
massive accumulation of complement activation products, such as C3-
fragments and components of TP, or it might be additional and abnormally  
arranged GBM constituents, produced after stimulation by the C activation. 
Profound hypocomplementemia has been observed in MPGN II, and this is a 
remarkable distinction between MPGN II and aHUS (68, 80, 150, 164). It is most 
likely that hypocomplementemia is not caused by the kidney pathology since 
bilateral nephrectomy did not affect the hypocomplementemia (242). It is, 
however, likely that vigorous AP activation in plasma is needed to generate 
high amount of C3b depositions in GBM leading to the pathology of MPGN II. 
So far there are still many questions concerning the pathology of 
MPGN II. We may ask why endothelial damage is not as severe in MPGN II as 
in aHUS? Although MPGN in FH deficient mice has similarities to human 
MPGN II, it remains unknown why the paramesangial deposits and mesangial 
cell proliferation are seen only in human and pig MPGN, not in the FH 
deficient mice. 
 
7.3 FH mutations in aHUS 
 
Recently, genetic and functional studies of aHUS patients have shown clear 
association between FH mutations and the disease. So far, however, there is no 
apparent linear relationship between particular mutations and the clinical 
presentations. At present, it is possible to conclude only that the alterations in 
the function of FH predispose individuals to aHUS. 
There are aHUS patients that have been reported with both dominant 
and recessive pedigrees and mutations found either as heterozygous or 
homozygous form, respectively. Also there are patients with only one attack of 
aHUS and those with chronic symptoms. In contrast with the mutations 
associated with MPGN II, aHUS-related mutations rarely result in 
hypocomplementamia or decreased plasma levels of FH. Interestingly, the 
most aHUS-related mutations are missense mutations and cluster within SCRs 
19-20, a region of FH that is not required to regulate complement activation in 
plasma (86, 148, 209). Recently, it has demonstrated that mutations with SCRs 
19-20 of FH can cause reduced binding to the central complement component 
C3b or its fragment C3d, to heparin, as well as to endothelial cells (210). 
Furthermore we showed in article III that the impaired binding of FH to 
endothelial cells is mediated by the alteration in the carboxy-terminal 
heparin/glycosaminoglycan binding site, suggesting that the damage to 
endothelial cells in aHUS is caused by a defect in the 
heparin/glycosaminoglycan binding site of the mutated patient FH. Our 
results in article IV showed that the carboxy-terminal domains 18-20 of mFH 
mediate accumulation to kidney glomeruli in vivo. It remains to be tested with 
site-directed mutants if this accumulation is lost upon aHUS-type missense 
mutations and if this kind of defect could have an effect on pathogenesis of at 
least some aHUS patients. 
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We are just beginning to understand the involvement of FH in the 
pathogenesis of aHUS. However the precise molecular mechanism for the 
disease remains unknown. Additional genetic differences might predispose 
certain patients to or protect them from the clinical disease and on the other 
hand it is possible that an external trigger is needed to initiate the pathological 
process. Nevertheless, the unique features of AP activation and the FH-
mediated control may shed some light on these open questions. Normal 
amount of FH in plasma limits AP activation both in the fluid phase and on the 
plasma-exposed surfaces thereby maintaining the normal C3 and factor B 
levels. The FH mutations in the majority of the aHUS patients are 
heterozygous, meaning that they have up to 50% of normal FH in plasma.  
Under normal circumstances half of the usual level of intact FH is 
sufficient to maintain the homeostasis. Some triggering events, such as 
inflammation, infection or tissue damage, can, however, cause additional AP 
activation and thereby initiate extraordinary C3b challenge to blood cells and 
endothelial cells. Also, independent of the origin of the inflammation, the 
released inflammatory mediators can cause retraction of endothelial cells or 
endothelial cell damage leading to exposure of the subendothelial matrix (215). 
During such conditions, maximal deposition and activity of FH, as provided by 
two intact alleles, might be essential to control the AP cascade in order to 
protect the damaged cells and tissues. For the aHUS patients that are 
heterozygous for FH mutations the reduced FH activity might be incapable of 
efficiently restricting the AP activation and to protect the exposed 
subendothelial matrix where membrane-bound C regulators are not present. 
This could allow propagation of the endothelial damage and initiate 
microvascular thrombosis. In future, this hypothesis needs to be proven.  
Clarification of the pathogenesis of aHUS will require detailed 
functional analyses of the individual mutations and to correlate those results 
with the phenotypes of individual affected patients. 
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